EA201890489A1 - CAR MACROPHAGES (MOTO-CAR) IN IMMUNOTHERAPY - Google Patents

CAR MACROPHAGES (MOTO-CAR) IN IMMUNOTHERAPY

Info

Publication number
EA201890489A1
EA201890489A1 EA201890489A EA201890489A EA201890489A1 EA 201890489 A1 EA201890489 A1 EA 201890489A1 EA 201890489 A EA201890489 A EA 201890489A EA 201890489 A EA201890489 A EA 201890489A EA 201890489 A1 EA201890489 A1 EA 201890489A1
Authority
EA
Eurasian Patent Office
Prior art keywords
car
moto
immunotherapy
macrophages
cancer
Prior art date
Application number
EA201890489A
Other languages
Russian (ru)
Inventor
Ким О'Нилл
Скотт Вебер
Original Assignee
Сандер Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сандер Байотек, Инк. filed Critical Сандер Байотек, Инк.
Priority claimed from PCT/IB2016/056140 external-priority patent/WO2017025944A2/en
Publication of EA201890489A1 publication Critical patent/EA201890489A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложены модифицированные макрофагальные иммунные клетки для лечения рака и других заболеваний.Proposed modified macrophage immune cells for the treatment of cancer and other diseases.

EA201890489A 2015-08-13 2016-10-13 CAR MACROPHAGES (MOTO-CAR) IN IMMUNOTHERAPY EA201890489A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562204935P 2015-08-13 2015-08-13
US201562240528P 2015-10-13 2015-10-13
US201615236421A 2016-08-13 2016-08-13
PCT/IB2016/056140 WO2017025944A2 (en) 2015-08-13 2016-10-13 Macrophage car (moto-car) in imunotherapy

Publications (1)

Publication Number Publication Date
EA201890489A1 true EA201890489A1 (en) 2018-08-31

Family

ID=57394619

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890489A EA201890489A1 (en) 2015-08-13 2016-10-13 CAR MACROPHAGES (MOTO-CAR) IN IMMUNOTHERAPY

Country Status (5)

Country Link
AU (1) AU2016305353B2 (en)
CA (1) CA2998406A1 (en)
EA (1) EA201890489A1 (en)
SG (1) SG10201914138WA (en)
ZA (1) ZA201801636B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9267948B2 (en) * 2009-12-30 2016-02-23 Brigham Young University Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof

Also Published As

Publication number Publication date
SG10201914138WA (en) 2020-03-30
AU2016305353A1 (en) 2018-04-12
AU2016305353B2 (en) 2022-10-13
CA2998406A1 (en) 2017-02-16
ZA201801636B (en) 2019-06-26

Similar Documents

Publication Publication Date Title
JOP20200192A1 (en) Anti-tigit antibodies
MX2021013837A (en) Combination immunotherapy approach for treatment of cancer.
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
TW201613648A (en) Compounds and compositions for immunotherapy
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
NZ731782A (en) Pyrrolobenzodiazepine-antibody conjugates
GEP20217317B (en) Combination therapy for the treatment of cancer
EA201692254A1 (en) IMMUNOMODULATING PROGENATIVE (IMP) CELLS
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
EP3164157A4 (en) Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
MX2017005975A (en) Anti-pdgf-b antibodies and methods of use.
PH12017500217A1 (en) Anti-orai1 antibody
PH12016501838A1 (en) Compounds and their methods of use
MX2015015232A (en) Monoclonal antibody directed against cxcr5.
MX2019014090A (en) Methods for the treatment of chronic pouchitis.
EA201890489A1 (en) CAR MACROPHAGES (MOTO-CAR) IN IMMUNOTHERAPY
EA201990824A1 (en) ANTIBODIES THAT CONTACT INTERLEUKIN-2 AND THEIR APPLICATION
EA201691907A1 (en) COMBINED THERAPY FOR CURAXIN
AU365961S (en) Clasp
EA201892645A1 (en) TUMOR LYMPHOCYTES PERMITTING FOR ADAPTIVE CELL THERAPY
AU359763S (en) Vehicle lighting